Remix Therapeutics, which is developing a new way to shut down the expression of cancer-causing genes, has seen the first signs of success in a rare salivary gland cancer.
The company is developing small-molecule drugs …
What health tech stands to gain as pharma goes DTC
When the Trump administration in September debuted TrumpRx.gov as part of its deal with Pfizer at “most favored nation” prices, my mind immediately turned to


